Latest Neuland Labs Stories
--Revenues Rose While Net Profits Increased Six-Fold Year-Over-Year-- HYDERABAD, India, May 10, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the 2013 fiscal year (FY) ended March 31, 2013. "Our initiatives to reduce costs and increase...
HYDERABAD, India, Feb. 13, 2013 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2013, ended December 31, 2012. Revenues for the third quarter of FY 2013 were $19.56 million (1.074 billion INR*), compared to...
HYDERABAD, India, Nov. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the second quarter of fiscal year (FY) 2013, ended September 30, 2012. Revenues for the second quarter of FY 2013 were $21.37 million (1.18 billion...
HYDERABAD, India, Aug. 10, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2013, ended June 30, 2012. "We are pleased that in the first quarter of the new fiscal year we reported the...
HYDERABAD, India, May 3, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the 2012 fiscal year (FY) ended March 31, 2012. "We are pleased to begin the new fiscal year with the successful closing of our rights offering, which...
HYDERABAD, India, Feb. 10, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2012, ended December 31, 2011. Revenues for the third quarter of FY 2012 were $21.6 million (1.10 billion INR*)...
HYDERABAD, India and NEW ORLEANS, Feb. 9, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will launch a mobile app version of its GuarD project management system at the Informex USA 2012 conference. Saharsh R. Davuluri, President of Contract Research at...
HYDERABAD, India, Nov. 3, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the second quarter of fiscal year (FY) 2012, ended September 30, 2011. Revenues for the second quarter of FY 2012 were $25.2 million (1.23 billion...
HYDERABAD, India, Aug. 5, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year (FY) 2012, ended June 30, 2011. "We are pleased to report that in the first quarter of the new fiscal year we continued to...
HYDERABAD, India, June 22, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011. "It is fitting that we formally launch our new...
